Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

HOWL

Werewolf Therapeutics Inc

Nov 14 • 04:00PM ET

0.9182

-0.0095 -1.02 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA BLUE BMRN EDIT RCKT SGMO CLLS ADVM SLDB

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.62	Insider Own	29.14%	Shs Outstand	47.27M	Perf Week	-20.16%
Market Cap	44.57M	Forward P/E	-	EPS next Y	-1.28	Insider Trans	-13.34%	Shs Float	34.66M	Perf Month	-45.02%
Enterprise Value	16.16M	PEG	-	EPS next Q	-0.35	Inst Own	31.80%	Short Float	2.60%	Perf Quarter	-30.96%
Income	-72.84M	P/S	-	EPS this Y	7.57%	Inst Trans	-13.61%	Short Ratio	1.11	Perf Half Y	-17.28%
Sales	0.00M	P/B	1.47	EPS next Y	14.82%	ROA	-66.32%	Short Interest	0.90M	Perf YTD	-37.96%
Book/sh	0.63	P/C	0.68	EPS next 5Y	-1.96%	ROE	-122.43%	52W High	2.38 -61.42%	Perf Year	-57.29%
Cash/sh	1.35	P/FCF	-	EPS past 3/5Y	39.54% -20.76%	ROIC	-122.61%	52W Low	0.60 54.32%	Perf 3Y	-58.64%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.79% 9.92%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-8.30%	Oper. Margin	-	ATR (14)	0.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.87	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	22.22	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.87	EPS Q/Q	6.32%	SMA20	-32.13%	Beta	0.79	Target Price	6.33
Payout	-	Debt/Eq	1.26	Sales Q/Q	-	SMA50	-41.67%	Rel Volume	0.89	Prev Close	0.93
Employees	46	LT Debt/Eq	1.01	Earnings	Nov 04 BMO	SMA200	-27.60%	Avg Volume	816.60K	Price	0.92
IPO	Apr 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.08% -	Trades		Volume	723,111	Change	-1.02%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-03-24	Initiated	JMP Securities	Mkt Outperform	$12
Aug-24-23	Initiated	Wedbush	Outperform	$9
Jun-06-23	Resumed	Jefferies	Buy	$11 → $12
Sep-10-21	Initiated	BofA Securities	Buy	$26
May-25-21	Initiated	SVB Leerink	Outperform	$29
May-25-21	Initiated	Jefferies	Buy	$22
May-25-21	Initiated	H.C. Wainwright	Buy	$32
May-25-21	Initiated	Evercore ISI	Outperform	$23

Nov-07-25 09:00AM	Werewolf Therapeutics Presents Data Expanding Its PREDATOR Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting (GlobeNewswire)
Nov-04-25 07:00AM	Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -7.63%
Oct-31-25 08:58AM	Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake (Zacks) -6.43%
Oct-29-25 01:45PM	Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised (Zacks)
Oct-28-25 02:26PM	BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy (Zacks)
02:54PM	Loading…
Oct-23-25 02:54PM	Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil (Zacks)
12:00PM	Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why (Zacks)
Oct-08-25 08:00AM	Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer (GlobeNewswire)
Oct-03-25 09:00AM	Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting (GlobeNewswire) +6.77%
Sep-08-25 05:03PM	Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Sep-02-25 08:00AM	Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-14-25 07:00AM	Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-13-25 08:55AM	XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates (Zacks) +12.50%
Aug-12-25 05:35PM	Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Aug-07-25 08:25AM	CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
12:30PM	Loading…
Jul-29-25 12:30PM	ReAlta Life Sciences Appoints Ellen Lubman as Chief Business Officer (Exec Edge)
Jul-09-25 08:00AM	Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit (GlobeNewswire)
Jun-12-25 08:00AM	Werewolf Therapeutics to Participate in the BIO International Convention (GlobeNewswire)
May-29-25 12:00PM	Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know (Zacks)
08:00AM	Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 04:01PM	HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 (GlobeNewswire) -5.26%
May-13-25 08:00AM	Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit (GlobeNewswire)
May-08-25 07:00AM	Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -5.54%
May-06-25 05:10PM	Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-05-25 08:05AM	Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting (GlobeNewswire)
08:00AM	Werewolf Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-25-25 10:00AM	Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline (Zacks)
Apr-17-25 08:00AM	Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer (GlobeNewswire) +8.37%
Mar-31-25 08:00AM	Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.61%
Mar-11-25 07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Mar-04-25 08:00AM	Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-24-25 07:30AM	Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors (GlobeNewswire)
Jan-14-25 08:35AM	Werewolf Therapeutics provides business update, highlights 2025 outlook (TipRanks)
Jan-13-25 08:00AM	Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook (GlobeNewswire)
Nov-20-24 08:00AM	Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference (GlobeNewswire)
Nov-07-24 09:02AM	Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) -8.20%
09:00AM	Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-24 08:00AM	Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE Molecule for Inflammatory Diseases (GlobeNewswire) -5.02%
Oct-20-24 06:04AM	Bank of America Predicts up to ~390% Surge for These 2 Strong Buy Stocks (TipRanks)
Oct-04-24 09:00AM	Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire)
Sep-03-24 08:00AM	Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.09%
Aug-08-24 08:15AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +8.19%
07:05AM	Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jun-25-24 07:00AM	Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (GlobeNewswire) -10.34%
Jun-01-24 09:00AM	Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors (GlobeNewswire)
May-30-24 08:00AM	Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire) +5.30%
May-23-24 05:00PM	Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting (GlobeNewswire) +5.52% -5.43%
May-03-24 01:53PM	HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-24-24 10:05AM	Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-23-24 08:00AM	Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting (GlobeNewswire) +5.75%
Apr-15-24 12:00PM	All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy (Zacks) +17.06%
Apr-05-24 04:30PM	Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting (GlobeNewswire) -9.12%
Apr-04-24 04:30PM	Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR Platform in Immunology-Based Diseases at AAI Annual Meeting (GlobeNewswire)
Mar-12-24 09:55AM	How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37% (Zacks)
Mar-07-24 02:52PM	HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
08:45AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-06-24 08:00AM	Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference (GlobeNewswire)
Mar-05-24 04:30PM	Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024 (GlobeNewswire)
Jan-08-24 07:00AM	Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook (GlobeNewswire)
Jan-04-24 04:05PM	Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors (GlobeNewswire) +20.69%
Nov-22-23 07:00AM	Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-14-23 04:25PM	Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-23 07:00AM	Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire) +47.44%
Oct-31-23 09:00AM	Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
Oct-27-23 04:58AM	Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength? (Zacks) +6.49%
Sep-27-23 09:00AM	Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire) +11.00%
Sep-11-23 04:05PM	Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124 (GlobeNewswire)
Sep-05-23 04:05PM	Werewolf Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-24-23 09:57AM	Nvidia upgraded, Estee Lauder downgraded: Wall Street's top analyst calls (The Fly) +26.74%
Aug-13-23 08:04AM	Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? (Simply Wall St.)
Aug-11-23 03:21PM	Werewolf Therapeutics Second Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
Aug-10-23 08:25AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jun-30-23 06:10AM	Institutions profited after Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) market cap rose US$11m last week but private equity firms profited the most (Simply Wall St.) +5.90%
Jun-01-23 07:00AM	Werewolf Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) +14.42%
May-11-23 08:35AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -8.88%
07:00AM	Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-01-23 07:00AM	Werewolf Therapeutics to Participate in May Investor Conferences (GlobeNewswire) +5.49%
Apr-19-23 10:00AM	Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE Molecule, in Cancer Immunology Research (GlobeNewswire)
Mar-23-23 08:25AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.24%
07:00AM	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-16-23 07:30AM	UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023 (GlobeNewswire)
Mar-15-23 07:30AM	Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023 (GlobeNewswire)
Feb-24-23 07:30AM	Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330 (GlobeNewswire) -13.77%
Feb-17-23 05:08AM	Investors in Werewolf Therapeutics (NASDAQ:HOWL) have unfortunately lost 53% over the last year (Simply Wall St.)
Feb-07-23 07:00AM	Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-20-23 05:16AM	Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) top owners are private equity firms with 42% stake, while31% is held by institutions (Simply Wall St.) +22.51%
Dec-12-22 10:22AM	Is Werewolf Therapeutics (NASDAQ:HOWL) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) +7.26%
Nov-10-22 09:00AM	Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE Molecule, at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
08:15AM	Werewolf Therapeutics, Inc. (HOWL) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 04:05PM	Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-07-22 07:00AM	Werewolf Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-01-22 07:00AM	Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors (GlobeNewswire) +19.57%
Aug-15-22 06:45AM	Shareholders in Werewolf Therapeutics (NASDAQ:HOWL) are in the red if they invested a year ago (Simply Wall St.)
Aug-11-22 07:00AM	Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +14.02%
Aug-03-22 07:00AM	Werewolf Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)
Jul-05-22 07:54AM	We Think Werewolf Therapeutics (NASDAQ:HOWL) Needs To Drive Business Growth Carefully (Simply Wall St.)

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EVNIN LUKE	Director	Nov 07 '25	Sale	1.11	43,950	48,785	3,743,524	Nov 12 07:49 PM
EVNIN LUKE	Director	Nov 11 '25	Sale	1.14	35,818	40,833	3,676,534	Nov 12 07:49 PM
EVNIN LUKE	Director	Nov 10 '25	Sale	1.18	31,172	36,783	3,712,352	Nov 12 07:49 PM
EVNIN LUKE	Director	Nov 12 '25	Sale	1.09	26,101	28,450	3,650,433	Nov 12 07:49 PM
MPM BioVentures 2014, L.P.	10% Owner	Nov 07 '25	Sale	1.11	68,480	76,013	5,836,240	Nov 12 07:32 PM
MPM BioVentures 2014, L.P.	10% Owner	Nov 11 '25	Sale	1.14	55,810	63,623	5,731,860	Nov 12 07:32 PM
MPM BioVentures 2014, L.P.	10% Owner	Nov 10 '25	Sale	1.18	48,570	57,313	5,787,670	Nov 12 07:32 PM
MPM BioVentures 2014, L.P.	10% Owner	Nov 12 '25	Sale	1.09	40,669	44,329	5,691,191	Nov 12 07:32 PM
GADICKE ANSBERT	10% Owner	Nov 07 '25	Sale	1.11	68,480	76,013	5,836,240	Nov 12 07:31 PM
GADICKE ANSBERT	10% Owner	Nov 11 '25	Sale	1.14	55,810	63,623	5,731,860	Nov 12 07:31 PM
GADICKE ANSBERT	10% Owner	Nov 10 '25	Sale	1.18	48,570	57,313	5,787,670	Nov 12 07:31 PM
GADICKE ANSBERT	10% Owner	Nov 12 '25	Sale	1.09	40,669	44,329	5,691,191	Nov 12 07:31 PM
MPM BioVentures 2014 (B), L.P.	Shareholder	Nov 10 '25	Proposed Sale	1.15	8,679	9,981		Nov 10 04:54 PM
UBS Oncology Impact Fund, L.P.	Shareholder	Nov 10 '25	Proposed Sale	1.15	107,463	123,582		Nov 10 04:54 PM
MPM Oncology Innovations Fund,	Shareholder	Nov 10 '25	Proposed Sale	1.15	28,657	32,956		Nov 10 04:53 PM
MPM BioVentures 2014, L.P.	Shareholder	Nov 10 '25	Proposed Sale	1.15	130,125	149,644		Nov 10 04:53 PM
MPM Asset Management LLC	Shareholder	Nov 10 '25	Proposed Sale	1.15	20,597	23,687		Nov 10 04:51 PM
MPM Asset Management Investors	Shareholder	Nov 10 '25	Proposed Sale	1.15	4,479	5,151		Nov 10 04:51 PM
EVNIN LUKE	Director	Nov 04 '25	Sale	1.22	90,164	110,000	3,853,195	Nov 06 07:43 PM
EVNIN LUKE	Director	Nov 06 '25	Sale	1.21	34,947	42,286	3,787,474	Nov 06 07:43 PM
EVNIN LUKE	Director	Nov 05 '25	Sale	1.22	30,774	37,544	3,822,421	Nov 06 07:43 PM
MPM BioVentures 2014, L.P.	10% Owner	Nov 04 '25	Sale	1.22	140,488	171,395	6,007,122	Nov 06 07:41 PM
MPM BioVentures 2014, L.P.	10% Owner	Nov 06 '25	Sale	1.21	54,452	65,887	5,904,720	Nov 06 07:41 PM
MPM BioVentures 2014, L.P.	10% Owner	Nov 05 '25	Sale	1.22	47,950	58,499	5,959,172	Nov 06 07:41 PM
GADICKE ANSBERT	10% Owner	Nov 04 '25	Sale	1.22	140,488	171,395	6,007,122	Nov 06 07:40 PM
GADICKE ANSBERT	10% Owner	Nov 06 '25	Sale	1.21	54,452	65,887	5,904,720	Nov 06 07:40 PM
GADICKE ANSBERT	10% Owner	Nov 05 '25	Sale	1.22	47,950	58,499	5,959,172	Nov 06 07:40 PM
MPM Asset Management Investors	Shareholder	Nov 04 '25	Proposed Sale	1.31	4,479	5,867		Nov 04 04:50 PM
MPM BioVentures 2014 (B), L.P.	Shareholder	Nov 04 '25	Proposed Sale	1.31	8,679	11,369		Nov 04 04:49 PM
UBS Oncology Impact Fund, L.P.	Shareholder	Nov 04 '25	Proposed Sale	1.31	107,463	140,777		Nov 04 04:48 PM
MPM Oncology Innovations Fund,	Shareholder	Nov 04 '25	Proposed Sale	1.31	28,657	37,541		Nov 04 04:47 PM
MPM BioVentures 2014, L.P.	Shareholder	Nov 04 '25	Proposed Sale	1.31	130,125	170,464		Nov 04 04:46 PM
MPM Asset Management LLC	Shareholder	Nov 04 '25	Proposed Sale	1.31	20,597	26,982		Nov 04 04:45 PM
EVNIN LUKE	Director	Oct 31 '25	Sale	1.28	73,192	93,686	4,003,728	Nov 03 07:11 PM
EVNIN LUKE	Director	Oct 30 '25	Sale	1.43	55,795	79,787	4,076,920	Nov 03 07:11 PM
EVNIN LUKE	Director	Nov 03 '25	Sale	1.29	60,369	77,876	3,943,359	Nov 03 07:11 PM
MPM BioVentures 2014, L.P.	10% Owner	Oct 31 '25	Sale	1.28	114,044	145,976	6,241,673	Nov 03 07:08 PM
MPM BioVentures 2014, L.P.	10% Owner	Oct 30 '25	Sale	1.43	86,936	124,318	6,355,717	Nov 03 07:08 PM
MPM BioVentures 2014, L.P.	10% Owner	Nov 03 '25	Sale	1.29	94,063	121,341	6,147,610	Nov 03 07:08 PM
GADICKE ANSBERT	10% Owner	Oct 31 '25	Sale	1.28	114,044	145,976	6,241,673	Nov 03 07:07 PM
GADICKE ANSBERT	10% Owner	Oct 30 '25	Sale	1.43	86,936	124,318	6,355,717	Nov 03 07:07 PM
GADICKE ANSBERT	10% Owner	Nov 03 '25	Sale	1.29	94,063	121,341	6,147,610	Nov 03 07:07 PM
MPM Asset Management Investors	Shareholder	Oct 30 '25	Proposed Sale	1.56	4,479	6,987		Oct 30 05:13 PM
MPM BioVentures 2014 (B), L.P.	Shareholder	Oct 30 '25	Proposed Sale	1.56	8,679	13,539		Oct 30 05:12 PM
MPM Asset Management LLC	Shareholder	Oct 30 '25	Proposed Sale	1.56	20,597	32,131		Oct 30 05:11 PM
UBS Oncology Impact Fund, L.P.	Shareholder	Oct 30 '25	Proposed Sale	1.56	107,463	167,642		Oct 30 05:10 PM
MPM Oncology Innovations Fund,	Shareholder	Oct 30 '25	Proposed Sale	1.56	28,657	44,705		Oct 30 05:10 PM
MPM BioVentures 2014, L.P.	Shareholder	Oct 30 '25	Proposed Sale	1.56	130,125	202,995		Oct 30 05:08 PM
EVNIN LUKE	Director	Oct 29 '25	Sale	1.55	86,154	133,539	4,132,715	Oct 29 07:22 PM
EVNIN LUKE	Director	Oct 27 '25	Sale	1.72	46,664	80,262	4,263,196	Oct 29 07:22 PM
EVNIN LUKE	Director	Oct 28 '25	Sale	1.64	44,327	72,696	4,218,869	Oct 29 07:22 PM
MPM BioVentures 2014, L.P.	10% Owner	Oct 29 '25	Sale	1.55	134,240	208,072	6,442,653	Oct 29 07:21 PM
MPM BioVentures 2014, L.P.	10% Owner	Oct 27 '25	Sale	1.72	72,709	125,059	6,645,961	Oct 29 07:21 PM
MPM BioVentures 2014, L.P.	10% Owner	Oct 28 '25	Sale	1.64	69,068	113,272	6,576,893	Oct 29 07:21 PM
GADICKE ANSBERT	10% Owner	Oct 29 '25	Sale	1.55	134,240	208,072	6,442,653	Oct 29 07:21 PM
GADICKE ANSBERT	10% Owner	Oct 27 '25	Sale	1.72	72,709	125,059	6,645,961	Oct 29 07:21 PM
GADICKE ANSBERT	10% Owner	Oct 28 '25	Sale	1.64	69,068	113,272	6,576,893	Oct 29 07:21 PM
MPM Asset Management Investors	Shareholder	Oct 27 '25	Proposed Sale	1.77	4,479	7,928		Oct 27 05:00 PM
MPM BioVentures 2014 (B), L.P.	Shareholder	Oct 27 '25	Proposed Sale	1.77	8,679	15,362		Oct 27 04:59 PM
MPM Asset Management LLC	Shareholder	Oct 27 '25	Proposed Sale	1.77	20,597	36,457		Oct 27 04:59 PM
UBS Oncology Impact Fund, L.P.	Shareholder	Oct 27 '25	Proposed Sale	1.77	107,463	190,210		Oct 27 04:59 PM
MPM Oncology Innovations Fund,	Shareholder	Oct 27 '25	Proposed Sale	1.77	28,657	50,723		Oct 27 04:58 PM
MPM BioVentures 2014, L.P.	Shareholder	Oct 27 '25	Proposed Sale	1.77	130,125	230,321		Oct 27 04:58 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 12 '25	Buy	0.86	320,913	275,985	6,021,969	May 14 06:08 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 14 '25	Buy	0.98	162,539	159,288	6,237,482	May 14 06:08 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 13 '25	Buy	0.98	52,974	51,915	6,074,943	May 14 06:08 PM
MPM BioVentures 2014, L.P.	10% Owner	Mar 27 '25	Sale	1.05	1,963	2,061	3,208,793	Apr 30 04:17 PM
EVNIN LUKE	Director	Mar 27 '25	Sale	1.05	2,425	2,546	4,309,860	Apr 30 04:09 PM
GADICKE ANSBERT	10% Owner	Mar 27 '25	Sale	1.05	4,386	4,605	6,718,670	Apr 30 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HOWL

Werewolf Therapeutics Inc

Upgrade your FINVIZ experience